Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. (Record no. 18688309)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01503 a2200409 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250515161552.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200906s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0091-2700 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1177/0091270008330161 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lefèvre, Gilbert |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20090625 |
| 245 00 - TITLE STATEMENT | |
| Title | Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of clinical pharmacology |
| Date of publication, distribution, etc. | Apr 2009 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 430-43 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Administration, Cutaneous |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Asian People |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Butyrylcholinesterase |
| General subdivision | blood |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cholinesterase Inhibitors |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Delivery Systems |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phenylcarbamates |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Rivastigmine |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | White People |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Büche, Monika |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sedek, Greg |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maton, Steve |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Enz, Albert |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lorch, Ulrike |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sagan, Cyriaque |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Appel-Dingemanse, Silke |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of clinical pharmacology |
| Related parts | vol. 49 |
| -- | no. 4 |
| -- | p. 430-43 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1177/0091270008330161">https://doi.org/10.1177/0091270008330161</a> |
| Public note | Available from publisher's website |
No items available.